相似文献
1
Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.
World J Gastroenterol. 2007 Feb 28;13(8):1208-13. doi: 10.3748/wjg.v13.i8.1208.
2
Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
World J Gastroenterol. 2007 Apr 7;13(13):1989-94. doi: 10.3748/wjg.v13.i13.1989.
3
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.
Acta Pharmacol Sin. 2006 Dec;27(12):1630-6. doi: 10.1111/j.1745-7254.2006.00459.x.
4
Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model.
Acta Pharmacol Sin. 2007 Mar;28(3):453-8. doi: 10.1111/j.1745-7254.2007.00532.x.
5
In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles.
World J Gastroenterol. 2009 Apr 28;15(16):1966-72. doi: 10.3748/wjg.15.1966.
6
Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.
Integr Cancer Ther. 2014 Nov;13(6):520-8. doi: 10.1177/1534735414547109. Epub 2014 Aug 22.
7
Large scale preparation of midkine antisense oligonucleotides nanoliposomes by a cross-flow injection technique combined with ultrafiltration and high-pressure extrusion procedures.
Int J Pharm. 2013 Jan 30;441(1-2):712-20. doi: 10.1016/j.ijpharm.2012.10.023. Epub 2012 Nov 6.
8
In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.
Histol Histopathol. 2007 Mar;22(3):285-9. doi: 10.14670/HH-22.285.
9
New Natural Pigment Fraction Isolated from Saw Palmetto: Potential for Adjuvant Therapy of Hepatocellular Carcinoma.
Int J Mol Sci. 2016 Aug 5;17(8):1277. doi: 10.3390/ijms17081277.
10
The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma.
J Vis Exp. 2015 Oct 9(104):52411. doi: 10.3791/52411.
引用本文的文献
1
Significance of Midkine Signaling in Women's Cancers: Novel Biomarker and Therapeutic Target.
Int J Mol Sci. 2025 May 17;26(10):4809. doi: 10.3390/ijms26104809.
2
Midkine-A novel player in cardiovascular diseases.
Front Cardiovasc Med. 2022 Sep 20;9:1003104. doi: 10.3389/fcvm.2022.1003104. eCollection 2022.
3
Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury.
Front Neurol. 2020 Oct 22;11:568814. doi: 10.3389/fneur.2020.568814. eCollection 2020.
4
Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.
Oncogene. 2020 Mar;39(10):2040-2054. doi: 10.1038/s41388-019-1124-8. Epub 2019 Dec 4.
5
Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.
Int J Clin Exp Pathol. 2015 May 1;8(5):5387-94. eCollection 2015.
6
Therapeutic potential of midkine in cardiovascular disease.
Br J Pharmacol. 2014 Feb;171(4):936-44. doi: 10.1111/bph.12537.
7
Neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, interacts with pleiotrophin, a heparin-binding growth factor.
Neurochem Res. 2010 Aug;35(8):1131-7. doi: 10.1007/s11064-010-0164-9. Epub 2010 Apr 6.
8
Midkine translocated to nucleoli and involved in carcinogenesis.
World J Gastroenterol. 2009 Jan 28;15(4):412-6. doi: 10.3748/wjg.15.412.
本文引用的文献
1
Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model.
Acta Pharmacol Sin. 2007 Mar;28(3):453-8. doi: 10.1111/j.1745-7254.2007.00532.x.
2
Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.
Leuk Res. 2007 Aug;31(8):1045-51. doi: 10.1016/j.leukres.2006.12.008. Epub 2007 Jan 30.
3
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.
Acta Pharmacol Sin. 2006 Dec;27(12):1630-6. doi: 10.1111/j.1745-7254.2006.00459.x.
4
Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Cancer. 2006 Aug 15;107(4):864-73. doi: 10.1002/cncr.22068.
5
Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder.
J Cell Mol Med. 2005 Jul-Sep;9(3):655-61. doi: 10.1111/j.1582-4934.2005.tb00495.x.
6
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
Acta Pharmacol Sin. 2005 Jun;26(6):762-8. doi: 10.1111/j.1745-7254.2005.00762.x.
7
Midkine induced growth of ameloblastoma through MAPK and Akt pathways.
Oral Oncol. 2004 Mar;40(3):274-80. doi: 10.1016/j.oraloncology.2003.08.011.
8
Angiogenic and angiostatic factors in the molecular control of angiogenesis.
Q J Nucl Med. 2003 Sep;47(3):149-61.
9
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
J Biol Chem. 2002 Sep 27;277(39):35990-8. doi: 10.1074/jbc.M205749200. Epub 2002 Jul 16.
10
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.
Surg Oncol. 2002 Jun;11(1-2):85-100. doi: 10.1016/s0960-7404(02)00013-0.
Zotero 插件